Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years
Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years
复制标题
DOI：
10.1016/j.ygyno.2018.06.023
复制
发表时间：
2018-09-01
影响因子：
4.7
通讯作者：
Monk, Bradley J.
中科院分区：
文献类型：
--
作者：
Leath, Charles A., III;Monk, Bradley J.
自1970年以来，妇科肿瘤组（GOG）一直处于评估和帮助实施宫颈癌管理方面突破性和范式改变研究的最前沿。虽然这种影响的最引人注目的例子是1999年发表的一系列临床试验，评估了各种临床情况下的患者（包括局部晚期和根治性子宫切除术后的患者）的放化疗与单独放疗，但研究仍在继续进一步完善和改进治疗。2014年，根据GOG方案240的结果，贝伐珠单抗成为美国首个批准的妇科癌症靶向治疗。最近，GOG的临床试验工作正在改变所有临床场景的护理标准。最后，强调生存和特殊人群现在是最优先事项。(C)2018爱思唯尔公司All rights reserved.
Since 1970, the Gynecologic Oncology Group (GOG) has been at the forefront of evaluating and helping to implement ground breaking and paradigm changing research in the management of cervical cancer. While the most dramatic example of this impact was a series of clinical trials published in 1999 that evaluated chemoradiation therapy versus radiation therapy alone for patients with various clinical scenarios, including both locally advanced as well as post radical hysterectomy patients, investigation has continued to further refine and improve therapy. In 2014, based on the results of GOG protocol 240, bevacizumab became the first approved targeted therapy in a gynecologic cancer in the United States. Most recently, clinical trial work from the GOG is changing the standard of care for all clinical scenarios. Finally, an emphasis on survivorship and special populations are now top priorities. (C) 2018 Elsevier Inc. All rights reserved.